Like you I was thinking with all of these announcements of the DX3 cell line, team strengthening with Dr. Tunstall, CBCF funding small $ but meaningful, DX1 potentially reducing cancer metastasis and the highly anticipated engineering run. All of the above postive announcements plus the bio's index we are yet to see a rerate and see the gap fill from 0.03 to 0.037. This created on open by our 1st engineering run. It is frustrating but as long as we tick all the right boxes sooner or later the sentiment shift. GLTAH
PAB Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
